#United States #New York #Levi & Korsinsky #Fractyl Health #GUTS

Class Action Lawsuit Alert for Fractyl Health, Inc. (GUTS)

Investors in Fractyl Health, Inc., traded under the NASDAQ symbol GUTS, have significant news to consider. Levi & Korsinsky, LLP, a law firm specializing in securities litigation, has formally notified shareholders about a class action lawsuit that has been initiated on behalf of those who purchased GUTS securities from January 13, 2025, to January 29, 2026. The lawsuit centers on allegations of deceptive practices that potentially misled investors regarding the clinical effectiveness and operational issues linked to the company’s key medical device, the Revita DMR System.

Background of the Allegations

The legal action has arisen following a sharp decline in GUTS share value, which plummeted by approximately 74.86% between January 29 and January 30, 2026. This drastic drop equated to a cumulative loss of about $1.37 per share, severely affecting the shareholders who had invested based on misleading statements about the Revita system’s efficacy. Reports indicated GUTS described its Revita device as a breakthrough that could help sustain weight loss after patients ceased using GLP-1 drugs, a market valued at an impressive $175 billion.

However, disclosures made on January 29, 2026, led to public revelations that contradicted earlier claims. These disclosures included six-month data from GUTS’s REMAIN-1 study, which suggested that patients treated with the product had experienced a weight regain of 4.5%, while those in the control group experienced a 7.5% regain. This was a stark contrast to previous claims promoting the treatment’s success as groundbreaking.

Operational Issues at Key Study Sites

The lawsuit emphasizes operational failures at one of the six study sites, which was alleged to not have implemented sufficient lifestyle and dietary counseling programs. As a result, both treated and control groups reported unexpected weight regain, a critical point that was not disclosed to investors at the time the company promoted positive results.

Key findings from the lawsuit assert that investors were misled about the consistency of study conditions and the overall effectiveness of the treatment. Statements regarding the study's efficacy were observed to omit vital variables that would have painted a clearer picture of the treatment's prospects.

Important Actions for Investors

Shareholders are urged to take note of the upcoming deadline for lead plaintiff applications, which is set for October 20, 2026. Those who purchased shares during the specified period and suffered financial losses may have the opportunity to recover their losses through this class action. Levi & Korsinsky has experience in representing investors in similar litigations and aims to guide aggrieved shareholders through this complex process.

Frequently Asked Questions

What is the focus of the GUTS class action?

The class action lawsuit revolves around accusations of materially misleading statements and omissions issued by Fractyl Health regarding its clinical trials and the Revita DMR System’s performance.

Who can join the lawsuit?

Investors who acquired GUTS securities during the designated class period may be eligible to join the lawsuit.

What is required from the investors?

To participate, investors should gather evidence including brokerage records that prove purchase dates, quantities of shares owned, and transaction details to assess their potential recovery without obligation.

With the impending deadline approaching, it is crucial for affected shareholders to assess their positions and consider their options. As stated by attorney Joseph E. Levi, this lawsuit raises critical questions about the responsibility to disclose clinical data effectively in the medical device industry. Investors should remain vigilant and informed as further developments unfold.

For those seeking to join the action or inquire for more detailed information, Levi & Korsinsky encourages individuals to reach out to discuss eligibility and recovery strategies without any upfront costs.